-
- 1800 2010
- EN
-1366x0.jpg)
News
Array
(
[0] => stdClass Object
(
[id] => 1343
[id_crawler] =>
[category_product] => NULL
[thumbnail] => 522616278_1073528404888826_9152796069906354447_n.jpg
[album] =>
[url_video] =>
[is_status] => 1
[is_featured] => 0
[is_form] => 1
[displayed_time] => 2025-07-25
[program] => 0
[number] => 1
[viewed] => 0
[type] =>
[type_career] =>
[level] =>
[address] =>
[address_career] =>
[expiration_time] => 0000-00-00
[created_time] => 2025-07-25 10:31:57
[updated_time] => 2025-07-25 15:03:58
[files] =>
[salary] =>
[time] =>
[created_by] => 63
[is_table_content] => 1
[language_code] => en
[slug] => A-reunion-after-28-years-between-a-french-vietnamese-woman-and-her-biological-parents-in-thanh-hoa-a-connection-of-blood-and-heart
[title] => A Reunion After 28 Years Between a French-Vietnamese Woman and Her Biological Parents in Thanh Hoa – A Connection of Blood and Heart
[description] => Among countless stories of human life, sometimes we come across a truly special journey — where family bonds that seemed to fade still quietly live on in every heartbeat. The story of Malia Bakeon (birth name: Bùi Thị Dung), a woman of Vietnamese origin currently living in France, is a deeply moving testament to that truth.
[content] => Born in Thanh Hoa, Malia did not grow up in the embrace of her biological parents due to difficult circumstances. Life led her to France at a very young age, where she was adopted. Though she had a peaceful childhood in a faraway land, Malia Bakeon always carried a deep yearning in her heart — to know who she really was, where she came from, and who brought her into this world.
A 28-Year Journey to Reconnect With Her Roots
For nearly three decades, Malia never stopped thinking about her biological parents. Faint childhood memories gave her the determination to embark on the journey to find her birth family. That journey was far from easy. But thanks to the support of the Vietnamese community, the spread of information through the media, and especially the advances in DNA testing at GENTIS, Malia gradually moved closer to the truth of her origins.
Then, on a special day, a miracle happened: she found her biological parents in Vietnam — after 28 long years of separation. A reunion that had once only existed in the dreams of a little girl finally became reality.
GENTIS – A Bridge of Truth and Love
In that emotional journey, GENTIS is proud to have accompanied Malia as a crucial bridge, confirming the blood ties between her and her family in Vietnam.
Through highly accurate DNA testing, GENTIS helped verify the biological relationship between Malia and her birth parents — a key step in making the long-awaited reunion come true.
At GENTIS, each DNA sample is not just biological data. It is a living story of human connection, of family, and the deep longing to rediscover one’s true self. We understand that behind every result are tears of joy, the laughter of reunion, and the first hugs after many years apart.
GENTIS always places accuracy and professional ethics as its highest priorities. Every DNA test at GENTIS follows strict protocols in line with international standards, supported by modern laboratory systems, a team of experienced experts, and meticulous quality control at every stage.
We don't just deliver results — we restore trust and peace of mind for every client on their journey to uncover the truth.
More Than Just Testing – A Journey to Reclaim One’s Identity
Malia Bakeon's story is not just a personal tale. It is a symbol of hope for thousands longing to reconnect with their roots and biological families.
GENTIS understands that knowing where you belong is a basic yet sacred human need. That’s why in every journey — whether it’s reuniting with birth parents, confirming family relationships, or affirming identity — GENTIS is committed to walking alongside you with the utmost dedication and professionalism.
GENTIS congratulates Malia Bakeon and her family on this miraculous reunion! May the bonds of family continue to grow stronger, bringing days filled with love and connection. We also sincerely thank Malia for choosing and trusting GENTIS. Her story is a source of inspiration that drives us to keep striving, continuing to be a trusted companion for millions of families — on the journey to rediscover their roots and affirm the value of genetic heritage.
[content_more] =>
[meta_title] => A Reunion After 28 Years Between a French-Vietnamese Woman and Her Biological Parents in Thanh Hoa –
[meta_description] => Among countless stories of human life, sometimes we come across a truly special journey — where family bonds that seemed to fade still quietly live on in every heartbeat.The story of Malia Bakeon (birth name: Bùi Thị Dung), a woman of Vietnamese origin cu
[meta_keyword] => GENTIS,ADN,Genetic
[thumbnail_alt] =>
[post_id] => 1343
[category_id] => 4
)
[1] => stdClass Object
(
[id] => 1342
[id_crawler] =>
[category_product] => NULL
[thumbnail] => 2abfe31698882ed67799.jpg
[album] =>
[url_video] =>
[is_status] => 1
[is_featured] => 0
[is_form] => 0
[displayed_time] => 2025-07-18
[program] => 0
[number] => 1
[viewed] => 0
[type] =>
[type_career] =>
[level] =>
[address] =>
[address_career] =>
[expiration_time] => 0000-00-00
[created_time] => 2025-07-18 13:19:22
[updated_time] => 2025-07-21 09:09:09
[files] =>
[salary] =>
[time] =>
[created_by] => 63
[is_table_content] => 1
[language_code] => en
[slug] => GENTIS-&-Dong-Do-hospital-bringing-genratest-solutions-closer-to-patients-with-infertility-issues
[title] => GENTIS & Dong Do Hospital – Bringing Genratest Solutions Closer to Patients with Infertility Issues
[description] => On the afternoon of July 17, 2025, at Dong Do General Hospital, representatives from GENTIS (Genetic Analysis Services JSC) had a working session and professional exchange with the hospital's team of obstetricians and reproductive specialists. The meeting focused on introducing and providing in-depth updates on the Genratest – an advanced tool that improves treatment outcomes in assisted reproductive technology (ART), especially for patients who have experienced repeated implantation failure (RIF).
[content] => The scientific meeting was attended by Dr. Tang Duc Cuong, Level II Specialist – Medical Director of Dong Do Hospital and Director of the Dong Do IVF Center; MSc. Dr. Ngo Thi Diem – Head of the Obstetrics Department of Dong Do Hospital; along with various experts, doctors, technicians, and nurses from the hospital.
During the technical session, MSc. Nguyen Thi Thanh Hang (GENTIS Specialist) presented a scientific report titled "Genratest Technology: Determining the Optimal Window of Implantation (WOI) for Embryo Transfer." The presentation garnered significant attention from all attendees, including medical professionals, technicians, and nurses.
Genratest is a test that analyzes gene expression in the endometrium to precisely determine each woman’s unique Window of Implantation (WOI) – the optimal time when the endometrium is most receptive to embryo implantation. The test involves an endometrial biopsy and next-generation sequencing (NGS) of over 200 genes related to endometrial receptivity. Based on this analysis, doctors can determine the best timing for embryo transfer to achieve the highest success rate.
MSc. Nguyen Thi Thanh Hang provided valuable insights into the Genratest, currently being developed and implemented by GENTIS.
Research shows that among patients with a history of repeated implantation failure, 30–35% have a displaced WOI compared to the standard. This means that continuing with standard embryo transfer timing could result in a high risk of failure – even if the embryo quality and uterine environment are good. Genratest represents a breakthrough in personalized IVF treatment, supporting clinicians in making accurate and timely decisions regarding embryo transfer, thereby increasing implantation rates and reducing unexplained IVF failures.
When questions arose regarding Genratest from Dong Do Hospital’s specialists, Ms. Duong Thi Phuong (Head of R&D at GENTIS) gave detailed explanations on the sampling, analysis, and result delivery process. The endometrial biopsy is taken during a natural or hormone-controlled cycle and processed in GENTIS's ISO 15189-certified laboratory. Results are available within 10–12 working days, giving doctors a scientific basis to adjust embryo transfer timing for the following cycle.
In addition to theoretical aspects, the session also featured notable clinical data from both Vietnamese and international studies. Personalized embryo transfer based on Genratest results has shown significantly improved clinical pregnancy rates. Genratest is considered a valuable tool for patients facing challenges on their journey to parenthood.
Dr. Tang Duc Cuong shared:“We highly appreciate the applicability of Genratest in modern IVF treatments. With a team of skilled doctors and the support of cutting-edge technology, we believe personalized treatment – especially embryo transfer – is the key to improving success rates and reducing the burden on patients.”
Dr. Tang Duc Cuong – Medical Director of Dong Do Hospital and Director of Dong Do IVF Center – engaged in a meaningful discussion about the Genratest solution from GENTIS.
The meeting also set the stage for future collaboration between GENTIS and Dong Do Hospital, particularly in incorporating Genratest into routine treatment protocols and clinical research. This marks a significant step toward enhancing the quality of infertility treatment in Vietnam, making molecular biotechnology more accessible and effective for the community.
[content_more] =>
[meta_title] => GENTIS & Dong Do Hospital – Bringing Genratest Solutions Closer to Patients with Infertility Issues
[meta_description] => On the afternoon of July 17, 2025, at Dong Do General Hospital, representatives from GENTIS (Genetic Analysis Services JSC) had a working session and professional exchange with the hospital's team of obstetricians and reproductive specialists
[meta_keyword] => GENTIS,Gẻnatest,Dong Do
[thumbnail_alt] =>
[post_id] => 1342
[category_id] => 4
)
[2] => stdClass Object
(
[id] => 1341
[id_crawler] =>
[category_product] => NULL
[thumbnail] => 2-1752034596.jpg
[album] =>
[url_video] =>
[is_status] => 1
[is_featured] => 0
[is_form] => 0
[displayed_time] => 2025-07-12
[program] => 0
[number] => 1
[viewed] => 0
[type] =>
[type_career] =>
[level] =>
[address] =>
[address_career] =>
[expiration_time] => 0000-00-00
[created_time] => 2025-07-12 10:15:24
[updated_time] => 2025-07-24 13:42:33
[files] =>
[salary] =>
[time] =>
[created_by] => 63
[is_table_content] => 1
[language_code] => en
[slug] => Diagnosis-and-treatment-of-genetic-diseases-advances-and-new-solutions-
[title] => Diagnosis and Treatment of Genetic Diseases: Advances and New Solutions
[description] => The diagnosis and treatment of genetic diseases have become one of the most rapidly advancing fields in medicine, bringing new hope to millions of patients around the world. With the development of technology, from early diagnostic techniques to optimized treatment methods, the detection and management of genetic disorders have become more accurate and effective than ever. These groundbreaking solutions not only improve patients' quality of life but also lay a solid foundation for the future.
[content] => Detecting Balanced Translocations in Preimplantation Embryos Using PGT Technology
MSc. Nguyen Van Huynh (GENTIS Specialist) presented the advantages of PGT-UPGRADE testing.
The detection and analysis of balanced translocations in preimplantation embryos are opening a new chapter in the search for "healthy seeds of life" for couples undergoing infertility treatment. This advanced technique enables the screening of potential genetic abnormalities from the earliest stages of embryonic development, allowing for precise selection of the best embryos for uterine transfer.
One of the most notable breakthroughs today is PGT-UPGRADE—a deep genetic analysis method developed by GENTIS using international-standard Next-Generation Sequencing (NGS) technology. In addition to comprehensively detecting aneuploidy across all 24 chromosomes, PGT-UPGRADE is specialized in identifying genetic balanced translocations—a factor that conventional tests often miss but may be the root cause of recurrent miscarriages, IVF failure, or congenital abnormalities.
In clinical practice, PGT-UPGRADE helps screen and select embryos that do not carry the same balanced translocation as either parent, thereby minimizing the risk of passing genetic abnormalities to the next generation and eliminating reproductive complications caused by such translocations. It is the optimal solution for couples with balanced translocations—allowing proactive selection of genetically normal embryos, increasing IVF success rates, reducing pregnancy risks, and offering the chance of welcoming a healthy baby.
Zygote Formation Abnormalities in IVF and Detection Methods
Dr. Bui Thi Phuong Hoa (Head of Research and Training Department – Hanoi Hospital of Andrology and Infertility) presented on abnormalities during in vitro fertilization and their detection.
In IVF procedures, abnormalities in zygote formation are one of the main causes of implantation failure and unsuccessful pregnancies. These may include chromosomal number anomalies or genetic mutations that lead to severe disorders.
Today, the detection of such abnormalities relies heavily on advanced genetic testing technologies such as chromosomal analysis using NGS or CGH array methods. These tests allow early detection of abnormalities that might affect IVF success, enabling physicians to make appropriate decisions in selecting healthy embryos for transfer.
With support from these modern detection methods, IVF failure rates have significantly decreased. This not only helps families save time and costs but also minimizes the risk of passing hereditary diseases to their children. The increasing accuracy of these methods is building strong trust among couples on their journey to parenthood.
Developing Interpretation Software for Newborn Screening Using LC-MS/MS
MSc., Resident Doctor Dinh Thi Quynh Ngoc (GENTIS Specialist) reported on the development of interpretation software for newborn screening results using the LC-MS/MS method.
Newborn screening is one of the key measures for early detection of genetic and congenital metabolic disorders that can seriously affect the health and development of infants. Among screening techniques, Tandem Mass Spectrometry (UPLC-MS/MS) is increasingly becoming a modern method for accurately identifying abnormalities from birth. However, one of the current major challenges is result interpretation—which requires a combination of high precision and rapid processing speed.
To meet this need, the development of interpretation software for newborn screening using mass spectrometry has emerged as a breakthrough in enhancing healthcare service quality. These software solutions automate the entire data analysis process and assist doctors in making timely and accurate clinical decisions—from monitoring to treatment.
In particular, leading institutions in genetics in Vietnam, such as GENTIS, are investing in building advanced interpretation systems that optimize analysis performance and reduce errors during result reading. The participation of experienced units like GENTIS not only enhances the reliability of screening systems but also promotes the application of high technology in precision medicine in Vietnam.
GENTIS – A Trusted Partner in the Diagnosis and Treatment of Genetic Disorders
GENTIS has established itself as a pioneer in genetic technology research and application, providing accurate testing services along with diagnostic and treatment support software. With advanced technologies and a team of experienced experts, GENTIS remains a reliable partner for hospitals, clinics, and genetic research centers. In addition to developing technical solutions, GENTIS also offers consultation to support physicians and families throughout the treatment process.
Thanks to continuous technological advances, methods such as PGT, newborn screening using mass spectrometry, and result interpretation software are transforming how genetic diseases are diagnosed and treated. As a leader in genetic testing, GENTIS not only improves healthcare quality but also helps reduce the prevalence of preventable genetic conditions.
[content_more] =>
[meta_title] => Diagnosis and Treatment of Genetic Diseases: Advances and New Solutions
[meta_description] => The diagnosis and treatment of genetic diseases have become one of the most rapidly advancing fields in medicine, bringing new hope to millions of patients around the world.
[meta_keyword] => GENTIS,genetic
[thumbnail_alt] =>
[post_id] => 1341
[category_id] => 4
)
[3] => stdClass Object
(
[id] => 1340
[id_crawler] =>
[category_product] => NULL
[thumbnail] => nht05500.jpg
[album] =>
[url_video] =>
[is_status] => 1
[is_featured] => 0
[is_form] => 0
[displayed_time] => 2025-07-12
[program] => 0
[number] => 1
[viewed] => 0
[type] =>
[type_career] =>
[level] =>
[address] =>
[address_career] =>
[expiration_time] => 0000-00-00
[created_time] => 2025-07-12 09:52:47
[updated_time] => 2025-07-24 13:35:15
[files] =>
[salary] =>
[time] =>
[created_by] => 63
[is_table_content] => 1
[language_code] => en
[slug] => GENTIS-accompanies-the-annual-scientific-conference-of-Phuong-Chau-healthcare-group-2025
[title] => GENTIS Accompanies the Annual Scientific Conference of Phuong Chau Healthcare Group 2025
[description] => On July 11, 2025, the Annual Scientific Conference of Phuong Chau Healthcare Group (ACP 2025) was successfully held in Can Tho City, attracting over 800 delegates, experts, and guests. With the theme “JCI & JCI Enterprise – The Symphony of Healthcare Operations,” this year’s event once again affirmed ACP’s reputation as one of the leading specialized medical scientific conferences in Vietnam. The conference serves as a platform connecting scientists, doctors, and healthcare professionals, while also updating attendees on medical advancements across various fields to improve healthcare service quality in the region.
[content] => As a supporting sponsor, GENTIS was honored to participate in the conference and received much attention and appreciation from the professional community. This was an opportunity for GENTIS to reaffirm its role in the fields of genetic analysis and precision medicine—key components in the modern healthcare ecosystem.
JCI – A Global Benchmark for Healthcare Quality
The theme “JCI & JCI Enterprise – The Symphony of Healthcare Operations” was not only a highlight of ACP 2025 but also a testament to Phuong Chau Healthcare Group’s journey in enhancing healthcare quality. JCI (Joint Commission International) is one of the world’s most rigorous standards for healthcare quality and safety, with over 2,500 stringent criteria, including patient safety, infection control, medication management, emergency response, quality management, and safety for healthcare workers.
Phuong Chau Healthcare Group is proud to be among the top 10 healthcare groups globally and the first in Southeast Asia to be accredited with JCI Enterprise. Additionally, 3 out of 4 hospitals in its network have achieved JCI accreditation: Phuong Chau Can Tho, Phuong Chau Soc Trang, and Phuong Nam. This milestone is not only a source of pride for Phuong Chau but also marks a significant step forward for Vietnam’s healthcare sector on the global stage.
ACP 2025 – Gathering Leading Domestic and International Experts
ACP 2025 brought together many of Vietnam’s top JCI-accredited hospitals, including Vinmec Central Park, FV Hospital, American International Hospital (AIH), Cao Thang Eye Hospital, and of course, the host—Phuong Chau Healthcare Group. The conference also featured international experts from The Medical City (Philippines)—a renowned ASEAN hospital with JCI accreditation—alongside leading specialists in Obstetrics, Gynecology, and Neonatology.
The conference was structured into 10 thematic sessions, with 36 in-depth presentations covering key topics such as:
- High-quality operational models and holistic employee care
- Safety in treatment
- Safety in laboratory and diagnostic services
- Safety in IT and healthcare infrastructure
- In-depth updates and notable clinical cases in Obstetrics, Gynecology, and Neonatology
The diversity and depth of the sessions reflect the medical community’s ongoing commitment to advancing knowledge, improving clinical practice, and adopting modern healthcare management models.
GENTIS – A Pioneer in Genetic Analysis, Partnering with Modern Medicine
As a pioneering institution in genetic testing and precision medicine, GENTIS brought groundbreaking solutions to ACP 2025 that support screening, diagnosis, and personalized treatment. The GENTIS booth at the event attracted special interest from hundreds of delegates and experts. Here, GENTIS showcased cutting-edge technologies already widely applied in leading IVF centers and hospitals:
- PGT Next: Detects aneuploidy/monosomy in embryos – enhancing success rates in assisted reproduction.
- PGT Upgrade: Identifies embryos carrying balanced translocations – reducing inherited disease risks.
- PGT-M for 100+ rare diseases: Screens for over 100 monogenic diseases – helping carrier couples select healthy embryos.
- PGT MAX 1: High-resolution genetic screening – increasing screening accuracy.
- Thrombophilia: Screens for gene mutations associated with clotting disorders – particularly important during pregnancy.
- Thalassemia: Screens for inherited anemia – minimizing the risk of having a child with thalassemia.
- Genratest: Determines the optimal implantation window – maximizing IVF treatment success.
Through these innovative products and services, GENTIS continues to bridge the gap between scientific research and practical application, contributing significantly to improving treatment outcomes and quality of life.
Commitment to a Sustainable Healthcare Mission
ACP 2025 stands as a clear testament to the effective collaboration between healthcare organizations, experts, scientists, and businesses. GENTIS is proud to accompany the conference in its mission to spread knowledge, foster professional connections, and build a healthcare system that is high-quality, safe, and patient-centered.
Looking ahead, GENTIS hopes to continue its partnership with ACP and both domestic and international partners to fulfill its mission: “Enhancing the intellect and physical well-being of Vietnamese people” through advanced, accurate, and personalized genetic testing solutions.
Raising Awareness and Promoting Reproductive Autonomy
World Population Day (July 11) is an opportunity for the international community to reflect on the challenges and opportunities in population and development. This year’s theme, "Reproductive Autonomy in a Changing World," emphasizes the importance of individual rights—particularly for women—in making decisions about reproductive health and family planning.
In her speech at the rally, Minister of Health Dao Hong Lan stressed:
“The revised Population Ordinance of 2025 has just been passed. It recognizes and respects the reproductive autonomy of individuals and couples—decisions made voluntarily and in accordance with their health conditions and circumstances. This spirit aligns perfectly with the message of this year's World Population Day.”
GENTIS representative together with MSc. Dr. Mai Trung Son – representative of the General Office for Population, Ministry of Health
In the face of demographic shifts, rapid urbanization, climate change, population aging, and persistent gender inequality, empowering individuals with reproductive decision-making has become more crucial than ever. It is not only a matter of human rights but also a key to achieving sustainable development goals.
GENTIS – Supporting Reproductive Health and Genetic Quality
At the event, MSc. Dr. Mai Trung Son, representative of the General Office for Population – Ministry of Health, commended GENTIS for its contributions to reproductive healthcare and improving population quality. He praised GENTIS’s strong sense of social responsibility and its active participation in the rally. The company’s involvement underscores the growing role of medical technology enterprises in supporting national population goals.
As a leader in the field of genetic testing, GENTIS has been making significant contributions to reproductive health and population quality improvement in Vietnam. By joining this important event alongside the Ministry of Health, GENTIS not only demonstrates its social commitment but also delivers a powerful message about the role of science and technology in protecting and promoting reproductive rights.
During the rally, GENTIS offered small gifts along with informational materials on solutions to help couples have healthy children—such as non-invasive prenatal testing (NIPT) and genetic testing in assisted reproduction. Through these services, GENTIS helps realize the right to access scientific information and the right to choose safe, healthy childbirth options—perfectly in line with the theme of World Population Day 2025.
In a society increasingly focused on genetic health and the well-being of future generations, GENTIS's genetic solutions are becoming essential tools for supporting Vietnam’s population policies. The World Population Day 2025 rally serves as a reminder of our collective responsibility. As a leading provider in reproductive support, GENTIS reaffirms its commitment to working alongside healthcare agencies and communities to protect reproductive rights, for a healthy and sustainable future for all generations of Vietnamese people.
[content_more] => [meta_title] => GENTIS Joins the General Office for Population – Ministry of Health in the Rally Celebrating World P [meta_description] => On the morning of July 11, 2025, in Hanoi, the General Office for Population – Ministry of Health, in collaboration with the United Nations Population Fund (UNFPA) in Vietnam, held a grand rally in response to World Population Day with the theme: "Reprodu [meta_keyword] => GENTIS [thumbnail_alt] => [post_id] => 1339 [category_id] => 4 ) [5] => stdClass Object ( [id] => 1338 [id_crawler] => [category_product] => NULL [thumbnail] => tin-tuc/the_best_2025/rabbit-1438.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2025-07-11 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-07-11 13:44:26 [updated_time] => 2025-07-21 15:00:06 [files] => [salary] => [time] => [created_by] => 1 [is_table_content] => 0 [language_code] => en [slug] => gentis-lot-top-10-lab-di-truyen-tot-nhat-viet-nam-tai-le-trao-giai-the-best-of-vietnam-2025 [title] => GENTIS Named One of Vietnam’s Top 10 Genetic Laboratories at The Best of Vietnam 2025 Awards [description] => On July 5, 2025, at The Best of Vietnam 2025 awards ceremony, Genetic Analysis Services Joint Stock Company (GENTIS) was honored to receive the prestigious award recognizing it as one of the Top 10 Genetic Laboratories in Vietnam. This recognition is a well-deserved testament to GENTIS’s persistent efforts, innovation, and pioneering spirit in advancing the field of genetics in Vietnam. [content] =>A Milestone Affirming Its Pioneering Role
The Best of Vietnam is a prestigious annual awards program that celebrates brands and enterprises with outstanding achievements and positive contributions to Vietnam’s economic, social, and technological development. This year’s program was co-organized by Intellectual Property and Innovation Magazine, the Vietnam Union of Science and Business, the Vietnam Institute for Standard Compliance and Quality, and various other reputable organizations.
To be honored, companies must pass a rigorous evaluation system based on international standards, including technological capabilities, quality management systems, expert teams, brand reputation, social contributions, and customer feedback.
Among all institutions in the field of genetic testing and analysis across the country, GENTIS stood out and was selected as one of Vietnam’s Top 10 Genetic Laboratories, thanks to its internationally standardized laboratories, advanced testing technologies, and a nationwide service network.
GENTIS proudly receives the Top 10 Genetic Laboratory award at The Best of Vietnam 2025 ceremony.
A Journey of Constant Innovation and Technological Investment
Founded in 2010, GENTIS was one of the first companies to bring genetic testing services closer to Vietnamese people. Starting with paternity testing, GENTIS has continuously expanded and invested in advanced services such as non-invasive prenatal testing (NIPT), preimplantation genetic testing (PGT), and genetic screening for hereditary diseases.
With a long-term strategic vision, GENTIS consistently invests in research and development, upgrades equipment, and applies cutting-edge technologies such as Next Generation Sequencing (NGS), Microarray, and Real-time PCR, ensuring the highest level of accuracy for every test.
All of GENTIS’s analyses are conducted in laboratories certified to CAP, ISO 15189:2022, and ISO/IEC 27001:2022 standards, strictly monitored according to international quality procedures. The team of specialists and technicians at GENTIS are not only highly qualified but also receive ongoing training from international partners and top medical universities both in Vietnam and abroad.
Mr. Bùi Quốc Kha – Deputy Director of GENTIS Ho Chi Minh City Branch – receives the Top 10 Genetic Laboratory Award.
GENTIS – A Trusted Brand
Beyond its focus on technology, GENTIS places great emphasis on customer experience and in-depth consultation services. Every client is guided by a professional team, with absolute confidentiality of personal information, and results are interpreted by top genetics experts.
GENTIS is currently a strategic partner of hundreds of hospitals, fertility centers, and clinics across the country. It also collaborates with various international institutions in genetic research and disease screening.
As of 2025, GENTIS has served millions of customers, many of whom have successfully applied genetic analysis results for early detection and timely intervention of genetic disorders—contributing to improved quality of life and reduced medical burden on society.
Furthermore, GENTIS actively engages in community programs, including free genetic testing, public seminars on genetics, and collaborative research with hospitals. These initiatives reflect GENTIS’s strong commitment to enhancing public health—especially in maternal and child care.
A Strong Commitment to Sustainable Development
Speaking at the award ceremony, Mr. Bùi Quốc Kha, Deputy Director of GENTIS Ho Chi Minh City Branch, said:
“Being named among the Top 10 Genetic Laboratories in Vietnam is a tremendous honor for GENTIS. It not only recognizes our relentless efforts over the past 15 years but also motivates us to continue our pioneering mission in genetic analysis. We are committed to further research, innovation, and investment to deliver optimal, accurate, and timely genetic testing solutions that enhance community health care.”
The event also gathered outstanding businesses from diverse sectors such as healthcare, technology, education, manufacturing, and finance—sharing development visions and affirming the role of Vietnamese enterprises in the era of global integration. At the same time, the program strongly supported the campaign “Vietnamese people prioritize using Vietnamese products”, a key policy encouraged by the Politburo for broad public implementation.
Certificate and trophy awarded to GENTIS as one of the Top 10 Genetic Laboratories in Vietnam.
Elevating Vietnamese Genetic Testing to the Global Stage
GENTIS’s success in Vietnam is just the beginning. The company is gradually expanding its influence regionally and globally through partnerships with international labs, research centers, and hospitals. GENTIS aims not only to offer modern genetic testing services to Vietnamese people but also to put Vietnam on the global map of genetic technology.
In the near future, GENTIS aspires to become a leading tech company in genetic analysis applications, helping make Vietnam a trusted medical destination in the region.
About GENTIS
Genetic Analysis Services Joint Stock Company (GENTIS), founded in 2010, is a pioneer in providing high-quality genetic testing services in Vietnam. With internationally accredited laboratories, modern technology, and a team of reputable experts, GENTIS delivers advanced genetic solutions for personalized, comprehensive health care and disease prevention.
Eurofins – A Global Leader in Scientific Services
Eurofins Scientific is a world-leading group specializing in testing, inspection, and certification services for quality management systems across food, consumer products, environment, pharmaceuticals, and genetic analysis. Founded in October 1987 in Nantes, France with just four employees, Eurofins began as a young science-based company. From the very beginning, Eurofins set a clear vision – "Testing for Life" – contributing to scientific progress and protecting public health.
After more than three decades of rapid growth, Eurofins has become one of the largest scientific service providers in the world, with:
-
Over 62,000 employees across more than 900 laboratories globally
-
A leading position in testing for food, pharmaceuticals, cosmetics, agriculture, and a strong presence in advanced fields such as materials science, genomics, forensics, consumer products, and clinical diagnostics
-
Operations in over 62 countries, forming a cross-border scientific network where technological advances are shared, applied, and optimized with a shared mission: To make the world a safer, healthier place to live
This remarkable growth is not only about scale but also embodies the Eurofins spirit – a unique identity in the scientific community characterized by continuous innovation, investment in technology, service quality enhancement, and most importantly, a commitment to building a safer, healthier world. Eurofins affirms its leadership in innovation, accuracy, and quality in life sciences – continually setting global trends and standards. It is home to some of the brightest minds, always at the forefront of research, technological applications, and global standard development.
GENTIS – A Vietnamese Mark in the Global Eurofins Network
In February 2022, GENTIS officially joined the global Eurofins family – a historic milestone for life sciences in Vietnam, as a pioneer in genetic analysis became part of one of the world’s leading healthcare groups.
The integration of GENTIS into Eurofins is not merely an expansion in scale but a strategic connection between a powerful international corporation and a Vietnamese pioneer in genetic testing.
As a trailblazer in Vietnam specializing in genetic and DNA testing, GENTIS has established a leading position with millions of trusted customers, a team of experts, and laboratories that meet international standards.
The transformation of Eurofins GENTIS into a foreign-invested company carries profound strategic significance:
-
Access to world-leading technologies, improving testing capacity and service quality
-
Participation in a global scientific research network, expanding professional collaboration and sharing international knowledge
-
Bringing high-quality genetic testing services closer to the Vietnamese population, contributing to better public healthcare
At the same time, GENTIS will become a strategic hub for Eurofins in Southeast Asia, contributing to the group's ambition to expand genetic testing services in this highly potential region.
Eurofins GENTIS – Strong Leadership, Forward to the Future
Eurofins GENTIS represents the synergy of global strength and local expertise – combining international stature with deep local understanding. This perfect integration aims to bring advanced genetic testing services to millions of people in Vietnam and the region.
With Eurofins' global technology, team, and network, along with a solid scientific foundation, Eurofins GENTIS officially enters a new stage of development – becoming a pioneer in genetic analysis, leading Vietnam, and aiming to lead Southeast Asia.
[content_more] => [meta_title] => Eurofins GENTIS – A Milestone in Bringing Vietnamese Genetic Science to the Global Stage [meta_description] => From a startup in France, Eurofins has grown into one of the world’s leading scientific groups, particularly in the field of biological testing, including medical testing, with over 900 laboratories worldwide. [meta_keyword] => GENTIS,Eurofins [thumbnail_alt] => [post_id] => 1335 [category_id] => 4 ) [7] => stdClass Object ( [id] => 1334 [id_crawler] => [category_product] => NULL [thumbnail] => f1faa4a7ec1c5b42020d.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2025-07-03 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-07-03 10:14:20 [updated_time] => 2025-07-25 08:53:35 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Gentis-to-present-oral-report-at-ESHRE-2025-with-Research-on-segmental-mosaic-embryo-transfer [title] => GENTIS to Present Oral Report at ESHRE 2025 with Research on Segmental Mosaic Embryo Transfer [description] => A scientific study conducted by GENTIS, in collaboration with experts from Genoma and several other institutions in Vietnam and around the world, has been selected for an oral presentation at the ESHRE 2025 conference. [content] =>ESHRE – The World’s Leading Annual Event in Reproductive Medicine
ESHRE (European Society of Human Reproduction and Embryology) is the largest international conference in the field of reproductive medicine and embryology. Held annually in July by the European Society of Human Reproduction and Embryology, the event brings together thousands of experts, researchers, physicians, and global health organizations to share knowledge, research findings, and the latest trends in the treatment of infertility.
In 2025, the ESHRE conference will take place at the Paris Convention Centre – Porte de Versailles, one of the most modern and largest venues in Europe, from June 29 to July 2, 2025. This is a valuable opportunity for healthcare professionals to update their knowledge, expand professional networks, and jointly advance the field of reproductive medicine – a domain deeply rooted in human compassion and care.
GENTIS Research on Segmental Mosaic Embryos Selected for Oral Presentation
GENTIS is honored to have its research project titled: “Decoding the clinical fate of segmental mosaic embryos: key predictors of implantation and pregnancy success”
(selected Vietnamese title: "Giải mã kết cục lâm sàng chuyển phôi khảm cấu trúc một phần: các yếu tố chủ đạo dự đoán sự thành công chuyển phôi và mang thai IVF")
chosen by the ESHRE Scientific Committee for oral presentation – the highest and most prestigious form of presentation at the conference.
The Study Focuses on Segmental Mosaic Embryos – A Promising Yet Controversial Path in IVF
The research centers on segmental mosaic embryos – a type of embryo containing both normal and abnormal cells due to errors in mitotic cell division. The use of such embryos in IVF has long been controversial, yet it presents a promising option when no euploid embryos (chromosomally normal) are available.
The main objective of the study is to evaluate the implantation potential, pregnancy outcomes, and live birth rates of segmental mosaic embryos, thereby identifying key predictors of clinical success and proposing safer embryo selection criteria for IVF practice.
Data and Research Methods
This is a retrospective study, analyzing data from 3,790 mosaic embryos recorded in the International Registry of Mosaic Embryo Transfers (IRMET) between 2017 and 2024. The methodology includes:
- Embryo classification:
- Segmental mosaic embryos: 1,567
- Whole-chromosome mosaic embryos: 1,723
- Euploid embryos: 19,258
- Embryo characteristics:
- Degree of mosaicism (percentage of abnormal cells)
- Type of abnormality (segmental deletion or duplication)
- Size of the affected chromosomal segment
- Embryo morphology (Inner Cell Mass – ICM, and Trophectoderm – TE)
- Timing of biopsy (Day 4–6)
- Clinical outcomes analyzed:
- Implantation rate
- Clinical pregnancy rate
- Live birth rate
- Miscarriage rate
- Statistical methods:
- Logistic regression analysis
- Chi-square tests
- Standardized sequencing platform for consistent results
Key Findings
The study revealed several important factors that directly influence the clinical success of mosaic embryo transfer, including:
- The ongoing pregnancy rate (OPR) for segmental mosaic embryos was 45.5%, higher than whole-chromosome mosaics (34.3%) but lower than euploid embryos (50%).
- Higher levels of mosaicism significantly reduced OPR:
- 50% success at 20% mosaicism
- 45% at 30–40%
- Only 27% at 60%
- Embryos with small deletions, particularly on short chromosomal arms, showed higher success rates compared to large deletions or duplications.
- Timing of biopsy strongly affected outcomes: biopsies done on Day 4–5 yielded better results than those on Days 5 or 6.
- Embryos with high-quality morphology (ICM and TE) achieved superior clinical outcomes.
These findings emphasize that embryo selection for mosaic transfer should be based on multiple integrated criteria, rather than solely relying on classification from PGT-A (Preimplantation Genetic Testing for Aneuploidy).
Significance and Contributions of the Study
This research represents the first large-scale dataset on segmental mosaic embryos, with contributions from 20 IVF centers worldwide. Its practical impact includes:
- Enhancing clinical understanding of mosaic embryo behavior
- Supporting more informed and optimized embryo selection
- Contributing to the standardization of PGT-A reporting criteria, ultimately improving the safety and effectiveness of mosaic embryo transfer
This study also marks an important milestone for GENTIS, showcasing its commitment to rigorous scientific research, alignment with global trends, and its mission to accompany patients on their journey through infertility treatment.
Being selected for an oral presentation at ESHRE 2025 is a proud achievement, not only for GENTIS but for Vietnam’s entire reproductive medicine community. We firmly believe that our continued efforts in research and innovation will enhance IVF success rates and expand the possibility of parenthood for millions of families around the world.
[content_more] => [meta_title] => GENTIS to Present Oral Report at ESHRE 2025 with Research on Segmental Mosaic Embryo Transfer [meta_description] => A scientific study conducted by GENTIS, in collaboration with experts from Genoma and several other institutions in Vietnam and around the world, has been selected for an oral presentation at the ESHRE 2025 conference. This marks a significant milestone, [meta_keyword] => GENTIS,ESHRE [thumbnail_alt] => [post_id] => 1334 [category_id] => 4 ) )
A Reunion After 28 Years Between a French-Vietnamese Woman and Her Biological Parents in Thanh Hoa – A Connection of Blood and Heart
GENTIS & Dong Do Hospital – Bringing Genratest Solutions Closer to Patients with Infertility Issues
Diagnosis and Treatment of Genetic Diseases: Advances and New Solutions
GENTIS Accompanies the Annual Scientific Conference of Phuong Chau Healthcare Group 2025
GENTIS Joins the General Office for Population – Ministry of Health in the Rally Celebrating World Population Day 2025: Shaping Population Policies for Human Rights and Sustainable Development
GENTIS Named One of Vietnam’s Top 10 Genetic Laboratories at The Best of Vietnam 2025 Awards
Eurofins GENTIS – A Milestone in Bringing Vietnamese Genetic Science to the Global Stage
GENTIS to Present Oral Report at ESHRE 2025 with Research on Segmental Mosaic Embryo Transfer
Please fill in the information below to receive our supports and consultations!
Please fill in the information below to receive our supports and consultations!
